With 25+ years in pharmaceutical development, Innovenn has deep knowledge of the sector and its regulations.
We’ve worked with numerous disciplines associated with the path to marketing approvals for chronic and rare disease management – from filing Investigational New Drug Applications (INDs), to enacting clinical programs continuing on through New Drug Application (NDA) submission.
Our integrated strategic planning services enable our partners to deliver new tools that are intended to support patients, enable precision medicine, improve outcomes and accelerate relevant scientific advances.
